Cairo – Mubasher: The Egyptian Drug Authority (EDA) has approved requests from 61 local companies to begin procedures to register Favipiravir medicine, a treatment for coronavirus (COVID-19), the Middle East News Agency (MENA) reported on Tuesday.
There four companies that have already completed the registration procedures and obtained the final approval.
Moreover, the EDA also approved requests from 27 pharmaceutical companies to begin the registration procedures to manufacture Remdesivir drug, which is used in treating many COVID-19 cases, in addition to granting one local company the registration approval.
